Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 5
2010 9
2011 8
2012 8
2013 9
2014 14
2015 12
2016 11
2017 12
2018 12
2019 15
2020 23
2021 16
2022 21
2023 28
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Intensive Re-Induction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory High-Grade Myeloid Neoplasms.
Kopmar NE, Othus M, Quach K, Rasmussen A, Schonhoff K, Becker PS, Walter RB, Halpern AB, Salit R, Cassaday RD, Shustov A, Stewart FM, Oehler VG, Scott BL, Sandmaier BM, Lee SJ, Estey EH, Percival MM. Kopmar NE, et al. Among authors: othus m. Transplant Cell Ther. 2024 May 4:S2666-6367(24)00376-2. doi: 10.1016/j.jtct.2024.05.002. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38710302
SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
Patel SP, Guadarrama E, Chae YK, Dennis MJ, Powers BC, Liao CY, Ferri WA Jr, George TJ, Sharon E, Ryan CW, Othus M, Lopez G, Blanke CD, Kurzrock R. Patel SP, et al. Among authors: othus m. Cancer. 2024 Feb 15. doi: 10.1002/cncr.35243. Online ahead of print. Cancer. 2024. PMID: 38358334
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
Appelbaum JS, Wei AH, Mandrekar SJ, Tiong IS, Chua CC, Teh TC, Fong CY, Ting SB, Weber D, Benner A, Hill H, Saadati M, Yin J, Stone RM, Garcia-Manero G, Erba HP, Uy GL, Marcucci G, Larson RA, Thomas A, Freeman SD, Almuina NM, Döhner K, Thomas I, Russel NH, Döhner H, Othus M, Estey EH, Walter RB. Appelbaum JS, et al. Among authors: othus m. Leukemia. 2024 Feb;38(2):389-392. doi: 10.1038/s41375-024-02143-8. Epub 2024 Jan 23. Leukemia. 2024. PMID: 38263433 No abstract available.
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford BT, Scumpia PO, Lo RS, Othus M, Ribas A. Algazi AP, et al. Among authors: othus m. Cancer. 2024 May 15;130(10):1784-1796. doi: 10.1002/cncr.35200. Epub 2024 Jan 23. Cancer. 2024. PMID: 38261444 Clinical Trial.
181 results